Very early pulmonary function decline in systemic sclerosis: longitudinal evidence from the STRIKE and EUSTAR VEDOSS cohorts

Mean forced vital capacity (FVC) at interstitial lung disease (ILD) diagnosis in EUSTAR is approximately 87%, suggesting a period of pulmonary function decline prior to ILD detection. Here we analysed longitudinal pulmonary function trajectories in patients with very early diagnosis of systemic sclerosis (VEDOSS) to identify lung function decline at this very early stage of disease. We performed a retrospective analysis of two independent VEDOSS cohorts from the STRIKE and EUSTAR databases. Patients were included at baseline if they fulfilled VEDOSS criteria but did not meet the 2013 ACR/EULAR systemic sclerosis classification criteria and had at least one follow-up pulmonary function test (PFT). Very Early pulmonary function decline was defined as an absolute ≥ 10% decline in forced vital capacity (FVC), or a 5–9% FVC decline accompanied by a ≥ 15% decline in diffusing capacity of the lung for carbon monoxide (DLCO), at any time during follow-up. Clinical features and available serum biomarkers were compared between progressors and non-progressors. A total of 455 patients (77 STRIKE; 378 EUSTAR) were included. PFT-defined lung function decline was observed in 22.1% of patients in the STRIKE cohort and 17.2% in the EUSTAR cohort. Baseline DLCO was reduced in both cohorts (STRIKE: 90% ±18; EUSTAR: 85% ±16) despite preserved FVC (STRIKE: 102% ±15; EUSTAR: 106% ±16). 46.3% of patients with lung function decline fulfilled the 2013 ACR/EULAR SSc classification criteria during follow-up. Serum markers of extracellular matrix (ECM) turnover comprising the Enhanced Liver Fibrosis (ELF) score, were higher in progressors at baseline and follow-up compared with non-progressors in the STRIKE cohort. Time-to-event analysis demonstrated a cumulative incidence of very early pulmonary function decline of 20.4% (95% CI 15.0–25.4) at 5 years in the combined cohort. A substantial minority of patients with VEDOSS demonstrate measurable pulmonary function decline prior to fulfilment of classification criteria. Elevated markers of ECM turnover support the presence of early fibrotic activity in this subgroup. Our findings warrant the implementation of early ILD detection strategies in patients with very early diagnosis of SSc even if they do not fulfil classification criteria for the disease.

Authors

Institutions

Publication Details

Journal
Arthritis Research & Therapy
Published
2026-11-13
DOI
https://doi.org/10.1186/s13075-026-03945-0
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Very early pulmonary function decline in systemic sclerosis: longitudinal evidence from the STRIKE and EUSTAR VEDOSS cohorts

S. Blaise, Roberta Foti, Andra Rodica Balanescu, Marco Matucci‐Cerinic et al.
Arthritis Research & Therapy
Systemic Sclerosis and Related Diseases
article

Very early pulmonary function decline in systemic sclerosis: longitudinal evidence from the STRIKE and EUSTAR VEDOSS cohorts

S. Blaise, Roberta Foti, Andra Rodica Balanescu, Marco Matucci‐Cerinic, Yannick Allanore, Stefano Di Donato, Silvia Bellando-Randone, Francesco Del Galdo, V. Smith, Veronica Batani, Radim Bečvář, Lucy Thornton, Maria De Santis, Emmanuel Chatelus, Jelena Colic, Gabór Kumánovics, Vishal Kakkar, Lesley-Anne Bissell, Ulf Müeller-Ladner, Florenzo Iannone, Nicola Ortalli, Katja Perdan Pirkmajer
article en

Abstract

Mean forced vital capacity (FVC) at interstitial lung disease (ILD) diagnosis in EUSTAR is approximately 87%, suggesting a period of pulmonary function decline prior to ILD detection. Here we analysed longitudinal pulmonary function trajectories in patients with very early diagnosis of systemic sclerosis (VEDOSS) to identify lung function decline at this very early stage of disease. We performed a retrospective analysis of two independent VEDOSS cohorts from the STRIKE and EUSTAR databases. Patients were included at baseline if they fulfilled VEDOSS criteria but did not meet the 2013 ACR/EULAR systemic sclerosis classification criteria and had at least one follow-up pulmonary function test (PFT). Very Early pulmonary function decline was defined as an absolute ≥ 10% decline in forced vital capacity (FVC), or a 5–9% FVC decline accompanied by a ≥ 15% decline in diffusing capacity of the lung for carbon monoxide (DLCO), at any time during follow-up. Clinical features and available serum biomarkers were compared between progressors and non-progressors. A total of 455 patients (77 STRIKE; 378 EUSTAR) were included. PFT-defined lung function decline was observed in 22.1% of patients in the STRIKE cohort and 17.2% in the EUSTAR cohort. Baseline DLCO was reduced in both cohorts (STRIKE: 90% ±18; EUSTAR: 85% ±16) despite preserved FVC (STRIKE: 102% ±15; EUSTAR: 106% ±16). 46.3% of patients with lung function decline fulfilled the 2013 ACR/EULAR SSc classification criteria during follow-up. Serum markers of extracellular matrix (ECM) turnover comprising the Enhanced Liver Fibrosis (ELF) score, were higher in progressors at baseline and follow-up compared with non-progressors in the STRIKE cohort. Time-to-event analysis demonstrated a cumulative incidence of very early pulmonary function decline of 20.4% (95% CI 15.0–25.4) at 5 years in the combined cohort. A substantial minority of patients with VEDOSS demonstrate measurable pulmonary function decline prior to fulfilment of classification criteria. Elevated markers of ECM turnover support the presence of early fibrotic activity in this subgroup. Our findings warrant the implementation of early ILD detection strategies in patients with very early diagnosis of SSc even if they do not fulfil classification criteria for the disease.

Arthritis Research & Therapy
University of Modena and Reggio Emilia (IT), University of Leeds (GB), Humanitas University (IT), Vita-Salute San Raffaele University (IT), Carol Davila University of Medicine and Pharmacy (RO), University of Cagliari (IT), Justus-Liebig-Universität Gießen (DE), Université Paris Cité (FR), Charles University (CZ), Chapel Allerton Hospital (GB), Leeds Teaching Hospitals NHS Trust (GB), Centre Hospitalier Universitaire de Grenoble (FR), Ljubljana University Medical Centre (SI), Ghent University (BE), National Institute for Health and Care Research (GB), Institute of Rheumatology (CZ), Hôpital Cochin (FR), Assistance Publique – Hôpitaux de Paris (FR), IRCCS Ospedale San Raffaele (IT), Hôpitaux Universitaires de Strasbourg (FR), Hôpital d'Hautepierre (FR), Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT), IRCCS Humanitas Research Hospital (IT), University of Florence (IT), University of Bari Aldo Moro (IT), University of Pecs (HU)
Good health and well-being
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon